COVID Vaccine Immunity in Kidney Transplant Recipients

COVID Vaccine Immunity in Kidney Transplant Recipients

50 end-stage renal disease (ESRD) patients whom have had at least 2 doses of messenger ribonucleic acid (mRNA) vaccine, and undergoing transplantation at the University of Alabama at Birmingham (UAB) will be enrolled. The third mRNA vaccine will be given 3 months post transplant, and the 4th mRNA vaccine will be given 3 months following this. Blood samples will be collected and shipped to Viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

50 ESRD patients on peritoneal dialysis or hemodialysis or not on immunosuppression, no prior transplant, no known history of COVID infection, whom have had at least 2 doses of mRNA vaccine, and undergoing transplantation at UAB will be enrolled, after signing the informed consent. The third mRNA vaccine will be given 3 months post transplant, and the 4th mRNA vaccine will be given 3 months following this. Blood samples will be collected and shipped to Viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

Inclusion Criteria:

• End Stage Renal Disease patients on peritoneal dialysis or hemodialysis or not on immunosuppression
• no prior transplant
• no known history of COVID infection
• had at least 2 doses of mRNA COVID vaccine
• undergoing transplantation at the University of Alabama at Birmingham
• multi-organ transplant allowed

Exclusion Criteria:

• active COVID infection
• participant is not vaccinated against COVID